Table 1 Baseline characteristics of study participants.
Variable* | Total (N = 66) | Responders (N = 50) | Non-responders (N = 16) | p-value |
|---|---|---|---|---|
Female sex, n (%) | 60 (90.9) | 46 (92.0) | 14 (87.5) | 0.63 |
Age at enrollment, mean (± SD) | 34.0 (1.2) | 35.0 (1.4) | 30.8 (2.0) | 0.16 |
LN duration, mean (± SD) | 5.7 (0.8) | 5.9 (1.0) | 4.8 (1.6) | 0.99 |
Lupus nephritis | 0.65 | |||
New-onset LN, n (%) | 28 (42.4) | 22 (44.0) | 6 (37.5) | |
Relapse LN, n (%) | 38 (57.6) | 28 (56.0) | 10 (62.5) | |
Laboratory findings | ||||
Creatinine (mg/dl) | 0.6 (0.5, 0.8) | 0.61 (0.5, 0.8) | 0.60 (0.6, 0.9) | 0.61 |
eGFR (ml/min/1.73m2) | 120.0 (102.2, 130.8) | 120.0 (106.5, 128.2) | 117.5 (95.8, 132.0) | 0.81 |
C3 (mg/dl) | 50.0 (40.0, 60.0) | 49.5 (41.0, 60.0) | 51.0 (38.5, 58.5) | 0.85 |
C4 (mg/dl) | 9.1 (5.3, 12.0) | 8.0 (5.3, 12.0) | 9.0 (5.5, 11.3) | 0.76 |
Proteinuria (g/day) | 1.8 (1.2, 3.0) | 1.9 (1.2, 3.8) | 1.6 (1.1, 2.0) | 0.21 |
SLEDAI | 16 (12, 18) | 16 (12.3, 18) | 16 (12, 17.3) | 0.78 |
Renal SLEDAI | 12 (8, 12) | 12 (8, 12) | 12 (11, 12) | 0.37 |
SDI | 0 (0, 1) | 0 (0, 1) | 1 (0, 1.5) | 0.29 |
Autoantibody | ||||
Anti-dsDNA, n (%) | 52 (78.8) | 42 (84.0) | 10 (62.5) | 0.09 |
Anti-Sm, n (%) | 24 (36.4) | 16 (32.0) | 8 (50.0) | 0.32 |
Anti-Ro, n (%) | 40 (60.6) | 27 (54.0) | 13 (81.3) | 0.10 |
Anti-La, n (%) | 12 (18.2) | 8 (16.0) | 4 (25.0) | 0.46 |
Anti-RNP, n (%) | 32 (48.5) | 26 (52.0) | 6 (37.5) | 0.47 |
Anti-APL, n (%)** | 14 (21.2) | 11 (22.0) | 3 (18.8) | 1.00 |
Biopsy class | 0.26 | |||
III, n (%) | 15 (22.7) | 13 (26.0) | 2 (12.5) | |
IV, n (%) | 31 (47.0) | 23 (46.0) | 8 (50.0) | |
III + V, n (%) | 11 (16.7) | 6 (12.0) | 5 (31.3) | |
IV+V, n (%) | 9 (13.6) | 8 (16.0) | 1 (6.3) | |
Renal histology (ISN/RPS) | ||||
AI, /24 | 7 (5, 10) | 8 (5.3, 10) | 5 (3.8, 8.5) | 0.20 |
CI, /12 | 2 (0.3, 3) | 2 (0, 3) | 1.5 (1, 3) | 0.63 |
Induction treatment | 0.14 | |||
MMF, n (%) | 54 (81.8) | 43 (86.0) | 11 (68.8) | |
MMF + TAC, n (%) | 12 (18.2) | 7 (14.0) | 5 (31.3) | |
